STOCK TITAN

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

GE HealthCare Technologies (Nasdaq: GEHC) has announced the pricing of a secondary public offering of 13,281,302 shares of its common stock. The company will not receive any proceeds from the sale, as GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank. Following this debt-for-equity exchange, Morgan Stanley & Co. will sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers. The offering is expected to close on November 12, 2024, subject to customary conditions.

GE HealthCare Technologies (Nasdaq: GEHC) ha annunciato la determinazione del prezzo di un'offerta pubblica secondaria di 13.281.302 azioni del suo capitale ordinario. La società non riceverà alcun ricavato dalla vendita, poiché GE Aerospace prevede di scambiare queste azioni per debito detenuto da Morgan Stanley Bank. Dopo questo scambio di debito per capitale, Morgan Stanley & Co. venderà le azioni agli sottoscrittori. J.P. Morgan, Citigroup e Morgan Stanley stanno fungendo da principali manager joint book-running. Si prevede che l'offerta si chiuda il 12 novembre 2024, soggetto a condizioni consuete.

GE HealthCare Technologies (Nasdaq: GEHC) ha anunciado el precio de una oferta pública secundaria de 13,281,302 acciones de su capital social. La compañía no recibirá ningún ingreso por la venta, ya que GE Aerospace planea intercambiar estas acciones por deuda que posee Morgan Stanley Bank. Tras este intercambio de deuda por capital, Morgan Stanley & Co. venderá las acciones a los suscriptores. J.P. Morgan, Citigroup y Morgan Stanley están actuando como principales gestores conjuntos. Se espera que la oferta cierre el 12 de noviembre de 2024, sujeto a condiciones habituales.

GE HealthCare Technologies (Nasdaq: GEHC)는 13,281,302주의 보통주에 대한 추가 공개 발행 가격을 발표했습니다. 회사는 판매로부터 어떠한 수익도 받지 않을 것이며, GE Aerospace는 이 주식을 Morgan Stanley Bank가 보유한 채무와 교환할 계획입니다. 이 채무-자본 교환 이후, Morgan Stanley & Co.는 이 주식을 인수자에게 판매할 것입니다. J.P. Morgan, Citigroup 및 Morgan Stanley가 공동 주관사로 참여하고 있습니다. 이 제안은 2024년 11월 12일에 종료될 것으로 예상되며, 일반적인 조건에 따릅니다.

GE HealthCare Technologies (Nasdaq: GEHC) a annoncé le prix d'une offre publique secondaire de 13 281 302 actions de son capital social. La société ne recevra aucun produit de la vente, car GE Aerospace prévoit d'échanger ces actions contre une dette détenue par Morgan Stanley Bank. Suite à cet échange de dette contre des actions, Morgan Stanley & Co. vendra les actions à des souscripteurs. J.P. Morgan, Citigroup et Morgan Stanley agissent en tant que principaux gestionnaires co-dépositaires. On s'attend à ce que l'offre se termine le 12 novembre 2024, sous réserve de conditions habituelles.

GE HealthCare Technologies (Nasdaq: GEHC) hat die Preisgestaltung für ein sekundäres öffentliches Angebot von 13.281.302 Aktien ihres Stammkapitals bekannt gegeben. Das Unternehmen wird aus dem Verkauf keine Einnahmen erzielen, da GE Aerospace plant, diese Aktien gegen Schulden von Morgan Stanley Bank einzutauschen. Nach diesem Schulden-gegen-Eigenkapital-Tausch wird Morgan Stanley & Co. die Aktien an die Emissionsbanken verkaufen. J.P. Morgan, Citigroup und Morgan Stanley fungieren als Hauptbuchführer. Die Emission soll am 12. November 2024 abgeschlossen werden, vorbehaltlich üblicher Bedingungen.

Positive
  • Debt reduction for parent company GE Aerospace through debt-for-equity exchange
Negative
  • Potential dilution of existing shareholders due to 13.28M share secondary offering
  • No proceeds from the offering will benefit GE HealthCare

Insights

This secondary offering represents a significant market event where GE Aerospace is effectively converting its debt to equity through Morgan Stanley. The offering of 13,281,302 shares will increase the public float of GEHC stock, potentially improving trading liquidity. With GEHC's current market cap of 40.36B, this offering represents approximately 3.3% of the company's value.

The transaction structure is notable - rather than a direct sale, GE Aerospace is exchanging shares for debt held by Morgan Stanley, who will then sell these shares to the market. This debt-for-equity swap helps GE Aerospace deleverage its balance sheet while providing a structured exit for part of its GEHC holdings. The involvement of major underwriters J.P. Morgan, Citigroup and Morgan Stanley adds credibility to the offering.

CHICAGO--(BUSINESS WIRE)-- GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below).

Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE Aerospace held by Morgan Stanley Bank, N.A. (the “MS Lender”), an affiliate of Morgan Stanley & Co. LLC, the selling stockholder in the Offering by designation of the MS Lender. Following the debt-for-equity exchange, if consummated, Morgan Stanley & Co. LLC, as the selling stockholder in the Offering, intends to sell the GEHC Shares to the underwriters in the Offering.

J.P. Morgan, Citigroup and Morgan Stanley are acting as the lead joint book-running managers for the Offering. The Offering is expected to close on November 12, 2024, subject to customary closing conditions.

The GEHC Shares will be offered from time to time in one or more transactions on The Nasdaq Stock Market LLC, in the over-the-counter market or through negotiated transactions or otherwise at prices prevailing at the time of sale, at prices related to prevailing prices or at negotiated prices.

The Offering is being made pursuant to an automatically effective shelf registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. A final prospectus supplement and accompanying prospectus describing the terms of the Offering will be filed with the SEC. You may obtain these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the final prospectus supplement and accompanying prospectus relating to the Offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Forward‐Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the size, timing or results of the Offering and the selling stockholders’ intent to offer shares of common stock, and reflect management’s current plans, estimates and expectations and are inherently uncertain. The inclusion of any forward-looking information in this release should not be regarded as a representation that the future plans, estimates or expectations contemplated will be achieved. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause actual results to differ materially from those described in the Company’s forward-looking statements include, but are not limited to, operating in highly competitive markets; our ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the Company’s ability to operate effectively as an independent, publicly-traded company; and the other factors detailed in the Company’s Registration Statement on Form S-3 filed on February 15, 2024, as well as other risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Please also see the “Risk Factors” section of the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Investor Relations:

Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com



Media:

Jennifer Fox

+1-414-530-3027

jennifer.r.fox@gehealthcare.com

Source: GE HealthCare Technologies Inc.

FAQ

How many shares are being offered in GE HealthCare's (GEHC) secondary offering?

GE HealthCare (GEHC) is offering 13,281,302 shares of its common stock in the secondary public offering.

When is GE HealthCare's (GEHC) secondary offering expected to close?

The secondary offering is expected to close on November 12, 2024, subject to customary closing conditions.

Will GE HealthCare (GEHC) receive any proceeds from the secondary offering?

No, GE HealthCare will not receive any proceeds from the sale of shares in the secondary offering or from the debt-for-equity exchange.

Who are the lead underwriters for GE HealthCare's (GEHC) secondary offering?

J.P. Morgan, Citigroup, and Morgan Stanley are acting as the lead joint book-running managers for the offering.

GE HealthCare Technologies Inc.

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Stock Data

40.36B
456.87M
3.09%
78.53%
2%
Health Information Services
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
CHICAGO